184 related articles for article (PubMed ID: 23436494)
1. Mifepristone for management of Cushing's syndrome.
Morgan FH; Laufgraben MJ
Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
[TBL] [Abstract][Full Text] [Related]
2. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
Castinetti F; Brue T; Conte-Devolx B
Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
[TBL] [Abstract][Full Text] [Related]
3. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
Castinetti F; Conte-Devolx B; Brue T
Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
[TBL] [Abstract][Full Text] [Related]
5. The use of mifepristone in the treatment of Cushing's syndrome.
Carroll T; Findling JW
Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
[TBL] [Abstract][Full Text] [Related]
6. Mifepristone: treatment of Cushing's syndrome.
Sartor O; Cutler GB
Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
[TBL] [Abstract][Full Text] [Related]
7. Mifepristone (Korlym) for Cushing's syndrome.
Med Lett Drugs Ther; 2012 Jun; 54(1392):46-7. PubMed ID: 22683927
[No Abstract] [Full Text] [Related]
8. Mifepristone (RU 486) in Cushing's syndrome.
Johanssen S; Allolio B
Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
[TBL] [Abstract][Full Text] [Related]
9. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
[TBL] [Abstract][Full Text] [Related]
10. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
Fein HG; Vaughan TB; Kushner H; Cram D; Nguyen D
BMC Endocr Disord; 2015 Oct; 15():63. PubMed ID: 26507877
[TBL] [Abstract][Full Text] [Related]
11. Drugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide.
Schteingart DE
Expert Opin Emerg Drugs; 2012 Sep; 17(3):279-83. PubMed ID: 22533823
[No Abstract] [Full Text] [Related]
12. Medical management of Cushing's syndrome.
Vance ML
Endocr Pract; 2013; 19(2):193. PubMed ID: 23598532
[No Abstract] [Full Text] [Related]
13. Merits and pitfalls of mifepristone in Cushing's syndrome.
Castinetti F; Fassnacht M; Johanssen S; Terzolo M; Bouchard P; Chanson P; Do Cao C; Morange I; Picó A; Ouzounian S; Young J; Hahner S; Brue T; Allolio B; Conte-Devolx B
Eur J Endocrinol; 2009 Jun; 160(6):1003-10. PubMed ID: 19289534
[TBL] [Abstract][Full Text] [Related]
14. Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.
Banerjee RR; Marina N; Katznelson L; Feldman BJ
Pediatrics; 2015 Nov; 136(5):e1377-81. PubMed ID: 26459648
[TBL] [Abstract][Full Text] [Related]
15. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).
Chu JW; Matthias DF; Belanoff J; Schatzberg A; Hoffman AR; Feldman D
J Clin Endocrinol Metab; 2001 Aug; 86(8):3568-73. PubMed ID: 11502780
[TBL] [Abstract][Full Text] [Related]
16. The medical management of Cushing's syndrome.
Morris D; Grossman A
Ann N Y Acad Sci; 2002 Sep; 970():119-33. PubMed ID: 12381547
[TBL] [Abstract][Full Text] [Related]
17. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
18. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.
Bertagna X; Bertagna C; Laudat MH; Husson JM; Girard F; Luton JP
J Clin Endocrinol Metab; 1986 Sep; 63(3):639-43. PubMed ID: 3734034
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid receptor blockers.
Molitch ME
Pituitary; 2022 Oct; 25(5):733-736. PubMed ID: 35507245
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.
Sun Y; Fang M; Davies H; Hu Z
Gynecol Endocrinol; 2014 Mar; 30(3):169-73. PubMed ID: 24205903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]